Emerging Market

PARIS (Reuters) - Turkey's achievement of investment-grade status crowns a decade of rapid growth, financial stability and political reform by a "tiger" economy on the seam of Europe and Asia, but the rising power still faces pitfalls in a dangerous...

WASHINGTON (Reuters) - Central banks got it right when they saved the world economy, but their unprecedented actions risk disruptive cross-border spillovers and potentially heavy losses when the time comes to reverse course, the IMF said on Thursday....

FRANKFURT, May 16 (Reuters) - Emerging markets will see the highest growth in premiums for insurance companies this year and next, while Europe lags, according to the world's biggest reinsurer, Munich Re. In a study published on Thursday, Munich Re...

By Sujata Rao LONDON, May 16 (Reuters) - A broad collapse of company profits in the developing world shows no sign of abating, forcing investors to tilt portfolios towards sectors such as healthcare or consumer goods where margins are more robust....

LONDON (Reuters) - A broad collapse of company profits in the developing world shows no sign of abating, forcing investors to tilt portfolios towards sectors such as healthcare or consumer goods where margins are more robust. What is evolving is in...

WASHINGTON (Reuters) - Central banks got it right when they saved the world economy, but their unprecedented actions risk disruptive cross-border spillovers and potentially heavy losses when the time comes to exit, the IMF said on Thursday. In the most...

* Turkey's monetary policy mix is unusually intricate * Criticised for failing to address inflation, loan growth * But gradually winning respect in financial markets * Achieves currency stability, weathers European crisis * Potential model for other...

HONG KONG (Reuters) - After 18 years as a banker at firms such as Citigroup and Nomura, Shaheryar Chishty took a different direction in late 2011, starting an investment firm that, among other things, helped guide Chinese and South Korean money into...

(Repeats to widen readership) By Deena Beasley LOS ANGELES, May 10 (Reuters) - The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end. Companies like Pfizer Inc...

By Mike Dolan LONDON, May 10 (Reuters) - Most investors see the yen's latest lunge as a byproduct of the rich world's money printing gambit and not a deliberate escalation in a notional currency war, but it is raising concerns about possible new...

By Deena Beasley LOS ANGELES, May 10 (Reuters) - The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end. Companies like Pfizer Inc and AstraZeneca have grown...

(Removes "XX" from headline) By Deena Beasley LOS ANGELES, May 10 (Reuters) - The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end. Companies like Pfizer Inc and...